Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,177,769 papers from all fields of science
Search
Sign In
Create Free Account
PDGFRB NP_002600.1:p.T681I
Known as:
Beta Platelet-Derived Growth Factor Receptor Thr681Ile
, Platelet-Derived Growth Factor Receptor 1 Thr681Ile
, Platelet-Derived Growth Factor Receptor Beta Thr681Ile
Expand
A change in the amino acid residue at position 681 in the platelet-derived growth factor receptor beta protein where threonine has been replaced by…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PDGRFB mutation‐associated myofibromatosis: Response to targeted therapy with imatinib
J. Weller
,
V. Keil
,
G. Gielen
,
U. Herrlinger
,
N. Schäfer
American Journal of Medical Genetics. Part A
2019
Corpus ID: 195871225
Heterozygous activating mutations in platelet‐derived growth factor receptor B (PDGFRB) have been recently identified as a cause…
Expand
2019
2019
Development of mouse models of angiosarcoma driven by p53
D. Salter
,
M. Griffin
,
+9 authors
V. Brunton
Disease Models & Mechanisms
2019
Corpus ID: 195188532
ABSTRACT Angiosarcomas are a rare group of tumours which have poor prognosis and limited treatment options. The development of…
Expand
2018
2018
Role of integrin alpha8 in murine model of lung fibrosis
C. Hung
,
Carole L Wilson
,
Y. Chow
,
L. Schnapp
PLoS ONE
2018
Corpus ID: 44110306
Background Integrin α8 (ITGA8) heterodimerizes with integrin β1 and is highly expressed in stromal cells of the lung. Platelet…
Expand
2017
2017
PDGFRβ-P2A-CreERT2 mice: a genetic tool to target pericytes in angiogenesis
H. Cuervo
,
B. Pereira
,
+4 authors
Chyuan-Sheng Lin
Angiogenesis
2017
Corpus ID: 25774822
Pericytes are essential mural cells distinguished by their association with small caliber blood vessels and the presence of a…
Expand
2016
2016
Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Takeshi Ishibashi
,
A. Yaguchi
,
+9 authors
N. Kiyokawa
Experimental Hematology
2016
Corpus ID: 10507465
Highly Cited
2013
Highly Cited
2013
Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs
N. Henderson
,
Thomas D. Arnold
,
+14 authors
D. Sheppard
Nature Network Boston
2013
Corpus ID: 55912983
Myofibroblasts are the major source of extracellular matrix components that accumulate during tissue fibrosis, and hepatic…
Expand
2012
2012
Cytogenetic changes in renal cell carcinoma: Basis for sensitivity and resistance to everolimus.
I. Caldwell
,
P. Oei
,
D. Ng
,
P. Fong
,
R. Broom
Journal of Clinical Oncology
2012
Corpus ID: 32089243
403 Background: The mTOR inhibitors have improved outcomes for pts with metastatic renal cell carcinoma (mRCC) but the duration…
Expand
2012
2012
Preclinical Development Sensitivity ofSelectedHumanTumorModels toPF-04217903 , a Novel Selective c-Met Kinase Inhibitor
H. Zou
,
Qiuhua Li
,
+13 authors
J. Christensen
2012
Corpus ID: 7455339
The c-Met pathway has been implicated in a variety of human cancers for its critical role in tumor growth, invasion…
Expand
2012
2012
Cytogenetic changes in renal cell carcinoma: Basis for sensitivity and resistance to everolimus.
I. Caldwell
,
P. Oei
,
D. Ng
,
P. Fong
,
R. Broom
Journal of Clinical Oncology
2012
Corpus ID: 20394867
403 Background: The mTOR inhibitors have improved outcomes for pts with metastatic renal cell carcinoma (mRCC) but the duration…
Expand
2005
2005
The small molecule tyrosine kinase inhibitor AMN 107 inhibits TEL-PDGFR and FIP 1 L 1-PDGFR in vitro and in vivo
E. Stover
,
Jing Chen
,
+11 authors
D. Gilliland
2005
Corpus ID: 12758844
AMN107 is a small molecule tyrosine kinase inhibitor developed, in the first instance, as a potent inhibitor of breakpoint…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE